Stockscreener 앱 받기
0.7975
44.23%
-0.6325
시간 외 거래:
.79
-0.0075
-0.94%
전일 마감가:
$1.43
열려 있는:
$0.93
하루 거래량:
3.67M
Relative Volume:
3.61
시가총액:
$37.71M
수익:
$5.12M
순이익/손실:
$-67.00M
주가수익비율:
-1.5101
EPS:
-0.5281
순현금흐름:
$-38.94M
1주 성능:
-52.53%
1개월 성능:
-39.12%
6개월 성능:
-89.02%
1년 성능:
-80.06%
1일 변동 폭
$0.7472
$0.9389
1주일 범위
$0.7472
$1.7382
52주 변동 폭
$0.7472
$11.41
Verrica Pharmaceuticals Inc Stock (VRCA) Company Profile
명칭
Verrica Pharmaceuticals Inc
전화
484-453-3300
주소
10 NORTH HIGH STREET, WEST CHESTER, PA
Verrica Pharmaceuticals Inc Stock (VRCA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-07-25 | 업그레이드 | Needham | Hold → Buy |
| 2023-03-22 | 개시 | Jefferies | Buy |
| 2023-02-13 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-05-25 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-05-14 | 개시 | RBC Capital Mkts | Outperform |
| 2020-12-24 | 재확인 | H.C. Wainwright | Buy |
| 2020-07-15 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2020-06-30 | 재확인 | H.C. Wainwright | Buy |
| 2020-06-24 | 개시 | Northland Capital | Outperform |
| 2020-03-24 | 개시 | Needham | Buy |
| 2019-02-21 | 개시 | H.C. Wainwright | Buy |
모두보기
Verrica Pharmaceuticals Inc 주식(VRCA)의 최신 뉴스
U.S. Stock market: Bluejay Diagnostics (+105.33%), Zoomcar Holdings (+180.40%), and Verrica Pharmaceuticals(+39.10%) among the most volatile stocks during mid day trading - Business Upturn
U.S. Stock market: Verrica Pharmaceuticals and Marqeta stocks plummet over 37%, while Avalon GloboCare soars 75% in volatile market trend - Business Upturn
Nasdaq Gains Over 100 Points; US Trade Deficit Widens In September - Benzinga
Verrica Pharmaceuticals (NASDAQ:VRCA) Releases Earnings Results, Misses Estimates By $0.12 EPS - MarketBeat
Verrica Pharmaceuticals stock hits 52-week low at $0.93 By Investing.com - Investing.com UK
Verrica Pharmaceuticals (NASDAQ:VRCA) Downgraded by Royal Bank of Canada to "Sector Perform" - MarketBeat
Verrica Pharmaceuticals Appoints Jayson Rieger as New CEO - Marketscreener.com
Verrica Pharmaceuticals earnings missed by $0.05, revenue fell short of estimates - Investing.com Canada
Shares of Verrica Pharmaceuticals Tumble Following 3Q Results, Operational Changes - MarketWatch
Verrica Pharmaceuticals Reports Third Quarter 2024 Financial Results and Announces Leadership Transition - GlobeNewswire
Verrica Pharmaceuticals Reports Third Quarter 2024 Financial Results and Announces Leadership - The Bakersfield Californian
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Short Interest Update - Defense World
Short Interest in Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Expands By 24.8% - MarketBeat
Verrica Pharmaceuticals Announces Acceptance of Two Abstracts Featuring Positive Preliminary Topline Results of VP-315 for the Treatment of Basal Cell Carcinoma at the 2024 Fall Clinical Dermatology Conference - GlobeNewswire
Pharma Co. Verrica Faces Derivative Suit Over FDA Inspection - Law360
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Verrica Pharmaceuticals (NASDAQ:VRCA) Given New $10.00 Price Target at TD Cowen - MarketBeat
Verrica shares price target cut by TD Cowen - Investing.com Canada
VERRICA PHARMACEUTICALS INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Verrica Pharmaceuticals Inc.VRCA - Business Wire
GLP-1 Receptor Agonist Market Set to Witness Significant Growth by 2024-2031:Verrica Pharmaceuticals, AbbVie - EIN News
Verrica Pharmaceuticals Inc (VRCA) Q2 2024 Earnings Call Highlights: Revenue Growth Amid Rising ... - Yahoo Finance
Verrica Pharmaceuticals reports board changes, non-compliance - Investing.com India
Verrica Pharmaceuticals reports board changes, non-compliance By Investing.com - Investing.com Australia
Recent Insider Activity Could Benefit Verrica Pharmaceuticals Inc (VRCA) - Knox Daily
Verrica Pharmaceuticals Strives for Nasdaq Compliance - TipRanks
Optinose Names Terry Kohler as CFO - MarketWatch
Optinose names Terry Kohler as new CFO By Investing.com - Investing.com UK
Optinose Appoints Terry Kohler as Chief Financial Officer - Marketscreener.com
The Significance of Moving Averages in Verrica Pharmaceuticals Inc Inc. (VRCA) Price Performance - The InvestChronicle
Verrica Pharmaceuticals Inc (VRCA)’s stock price range in the last year - US Post News
Financial Fitness Check: Examining Verrica Pharmaceuticals Inc (VRCA)’s Key Ratios - The Dwinnex
Verrica Pharmaceuticals Inc [VRCA] Shares Fall Approximately -61.64% Over the Year - Knox Daily
Verrica Pharmaceuticals Inc [VRCA] Revenue clocked in at $13.91 million, down -80.19% YTD: What’s Next? - The DBT News
Royal Bank of Canada Cuts Verrica Pharmaceuticals (NASDAQ:VRCA) Price Target to $11.00 - MarketBeat
This Tractor Supply Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday - MSN
Verrica downgraded to hold by Needham, cash position cited - MSN
Verrica Pharmaceuticals CEO to Present at Global Investment Conference - MSN
Madrigal Pharmaceuticals Joins H.C. Wainwright MASH Virtual Investor Conference - MyChesCo
The Price Is Right For Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Even After Diving 49% - Simply Wall St
Verrica Pharmaceuticals’ (VRCA) Hold Rating Reaffirmed at Needham & Company LLC - Defense World
A new trading data show Verrica Pharmaceuticals Inc (VRCA) is showing positive returns. - SETE News
Verrica Pharmaceuticals Announce Restructuring - citybiz
Verrica Pharmaceuticals Streamlines Operations to Enhance YCANTH Access - MSN
Verrica slashes costs, refocuses sales strategy By Investing.com - Investing.com South Africa
Verrica slashes costs, refocuses sales strategy - Investing.com
Verrica Pharmaceuticals announces workforce reduction By Investing.com - Investing.com Australia
Verrica Pharmaceuticals' (VRCA) Hold Rating Reiterated at Brookline Capital Management - MarketBeat
Verrica Pharmaceuticals’ (VRCA) “Hold” Rating Reiterated at Brookline Capital Management - Defense World
Verrica Pharmaceuticals Inc (VRCA) is an excellent investment, but the stock is overvalued/undervalued right now - US Post News
Verrica Pharmaceuticals Announces Restructuring of Commercial Organization - The Manila Times
Verrica Pharmaceuticals announces workforce reduction - Investing.com India
Verrica Pharmaceuticals Inc (VRCA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.02%
0.47%
자본화:
|
볼륨(24시간):